Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A

SSZSE:300760
185.38
CNY
+1.08
(+0.59%)
6.77EPS
25.22P/E
195.49BMarket Cap
Apr 23Next Earn

Total Valuation

CNY

As of September 30, 2026, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A carries a market capitalization of 195.49B, placing it among publicly traded companies globally. Its enterprise value stands at 180.82B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap195.49B
Enterprise Value180.82B

Important Dates

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A's next confirmed earnings release is scheduled for April 23, 2027.

Earnings Date4/23/2027

Share Statistics

As of September 30, 2026, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A has 1.21B shares outstanding.

Shares Outstanding1.21B

Valuation Ratios

As of September 30, 2026, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 25.22. The price-to-sales ratio is 5.66, and the price-to-book ratio stands at 4.74.

PE Ratio25.22
PS Ratio5.66
PB Ratio4.74
P/TBV Ratio8.20

Enterprise Valuation

As of September 30, 2026, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A trades at an EV/EBITDA multiple of 19.20 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.23 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 19.20 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 180.82B versus a market cap of 195.49B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales5.23
EV / EBITDA19.20
EV / EBIT19.20

Financial Position

As of September 30, 2026, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A maintains a current ratio of 2.38, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.65, indicating moderate leverage, while an interest coverage ratio of 385.16 demonstrates strong ability to service its debt obligations.

Current Ratio2.38
Quick Ratio1.54
Debt / Equity0.65
Debt / EBITDA0.03
Interest Coverage385.16

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 1.62M in revenue per employee across its workforce of 21,288.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee1.62M
Employee Count21,288.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A recorded 1.01B in income tax expense. That works out to an effective tax rate of 10.92, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 9.21B, leaving 7.75B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax1.01B
Effective Tax Rate10.92

Stock Price Statistics

CNY

As of the close on November 17, 2026, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A's stock has declined approximately 10.03% over the past 52 weeks. The 50-day moving average sits at 169.64, while the 200-day moving average is 163.91.

52-Week Price Change-10.03%
50-Day Moving Average169.64
200-Day Moving Average163.91

Income Statement

CNY

Over the twelve months ended September 30, 2026, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A generated 34.55B in revenue and converted that into 7.75B in net income, yielding earnings per share of 6.77. EBITDA reached 9.42B, while operating income came in at 10.29B.

Revenue34.55B
Gross Profit20.61B
Operating Income10.29B
Pretax Income9.21B
Net Income7.75B
EBITDA9.42B
EBIT9.42B
Earnings Per Share (EPS)6.77

Balance Sheet

CNY

As of September 30, 2026, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A holds 19.86B in cash and equivalents against 300.71M in total debt, resulting in a net debt position of -19.36B. Total book value stands at 41.20B, with working capital of 17.76B providing operational flexibility.

Cash & Cash Equivalents19.86B
Total Debt300.71M
Net Debt-19.36B
Equity (Book Value)41.20B
Book Value Per Share34.00
Working Capital17.76B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-2.08B

Margins

Over the twelve months ended September 30, 2026, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A posted a gross margin of 59.65, reflecting its pricing power and cost economics. The operating margin of 29.77 and net profit margin of 22.43 provide insight into operational efficiency.

Gross Margin59.65
Operating Margin29.77
Pretax Margin26.65
Profit Margin22.43
EBITDA Margin27.26

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A paid dividends of 4.24 per share. The dividend payout ratio of 59.40 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 3.04, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A shareholders.

Dividend Per Share4.24
Payout Ratio59.40
Shareholder Yield3.04

Scores

As of September 30, 2026, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A has an Altman Z-Score of 10.44, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score10.44